51,91 €
Produit Neuf
Ou 12,98 € /mois
- Livraison à 0,01 €
- Livré entre le 21 août et le 7 septembre
Brand new, In English, Fast shipping from London, UK; Tout neuf, en anglais, expédition rapide depuis Londres, Royaume-Uni;ria9781581121896_dbm
- Payez directement sur Rakuten (CB, PayPal, 4xCB...)
- Récupérez le produit directement chez le vendeur
- Rakuten vous rembourse en cas de problème
Gratuit et sans engagement
Félicitations !
Nous sommes heureux de vous compter parmi nos membres du Club Rakuten !
TROUVER UN MAGASIN
Retour
Avis sur Comparative Analysis And Benchmarking de Chen, Hung - Hsin Format Broché - Livre Économie
0 avis sur Comparative Analysis And Benchmarking de Chen, Hung - Hsin Format Broché - Livre Économie
Les avis publiés font l'objet d'un contrôle automatisé de Rakuten.
-
Der Mythus Des Zwangzigsten Jahrhunderts
Occasion dès 49,00 €
-
Elvis Presley On Tour Livre Usa 120 Pages 240 Photos Inedites ! Rare!
Occasion dès 59,00 €
-
Concise Oxford English Dictionary 12th Ed
23 avis
Neuf dès 42,95 €
Occasion dès 35,00 €
-
Harry Potter Collectible Quidditch Set (Includes Removeable Golden Snitch!)
Neuf dès 36,00 €
-
Complete Swedish Beginner To Intermediate Course
1 avis
Neuf dès 49,73 €
-
Alinea
1 avis
Occasion dès 55,00 €
-
Flight Attendants
Occasion dès 40,99 €
-
Mathématiques 1re S Et E : Géométrie Et Statistiques (Collection Terracher)
2 avis
Occasion dès 46,96 €
-
Des Bienfaits, 2 Tomes
1 avis
Occasion dès 45,80 €
-
Michael Kenna: Silver Haikus
3 avis
Neuf dès 52,52 €
-
Les Outils Dans Les Balkans Du Moyen Âge À Nos Jours
Occasion dès 50,00 €
-
Yoga Nidra
2 avis
Neuf dès 32,92 €
-
Communion
Neuf dès 44,71 €
-
Fragmentation And Repair
2 avis
Neuf dès 40,31 €
-
Impact Type
Neuf dès 39,73 €
-
Drive-In Dream Girls
Neuf dès 51,39 €
-
Google Pixel 10 Pro : Pixel 10 Pro
Neuf dès 41,99 €
-
Castles Of England
Neuf dès 37,66 €
-
Dc Finest: Hawkman: Wings Across Time
Neuf dès 42,16 €
-
Tusculanes, 2 Tomes (I-V)
Occasion dès 45,80 €
Produits similaires
Présentation Comparative Analysis And Benchmarking de Chen, Hung - Hsin Format Broché
- Livre Économie
Résumé :
This research of corporate strategy analysis implements comparative analysis and benchmarking to analyse and examine the corporate strategy of the pharmaceutical sectors of 4 international pharmaceutical companies. This research adopts the hybrid approach of combining qualitative and quantitative methods in a two stages research design. Quantitative method is applied first to deal with the comparative figures, and then qualitative method is used to find out the problem. The design of this multiple research includes three phases: data collection, analysis, and reporting. The findings of this research can be divided into 4 parts: R&D/marketing, technology alliances, strategic acquisitions and merger, and manufacturing. The drug innovative projects are recommended being developed within the company's familiar therapeutic areas in order to take its marketing advantage. Through this comparative analysis, some of this type of problems of these international pharmaceutical companies is identified. A big pharmaceutical company forming alliances with some small biotechnology companies has become a trend within pharmaceutical industry since 1980s. For pharmaceutical companies, to take advantage of R&D through biotechnology is the main purpose of alliances with small biotechnology companies. It is important to note that most pharmaceutical acquisitions belong to the type of absorption with high resource transferring and low autonomy. Due to the high profit margin and the essential importance of R&D and marketing, the operation management of manufacturing of pharmaceutical industry is relatively poor. The low asset utilisation rate pointed out this problem. Academic researches have revealed that existing theories of operation management of manufacturing, such as action research, set-up reduction, teamwork, continuous improvement, collaboration, and involvement, are applicable and beneficial to pharmaceutical industry rather than waiting for the technology breakthroughs....
Sommaire:
This research of corporate strategy analysis implements comparative analysis and benchmarking to analyse and examine the corporate strategy of the pharmaceutical sectors of 4 international pharmaceutical companies. This research adopts the hybrid approach of combining qualitative and quantitative methods in a two stages research design. Quantitative method is applied first to deal with the comparative figures, and then qualitative method is used to find out the problem. The design of this multiple research includes three phases: data collection, analysis, and reporting. The findings of this research can be divided into 4 parts: R&D/marketing, technology alliances, strategic acquisitions and merger, and manufacturing. The drug innovative projects are recommended being developed within the company's familiar therapeutic areas in order to take its marketing advantage. Through this comparative analysis, some of this type of problems of these international pharmaceutical companies is identified. A big pharmaceutical company forming alliances with some small biotechnology companies has become a trend within pharmaceutical industry since 1980s. For pharmaceutical companies, to take advantage of R&D through biotechnology is the main purpose of alliances with small biotechnology companies. It is important to note that most pharmaceutical acquisitions belong to the type of absorption with high resource transferring and low autonomy. Due to the high profit margin and the essential importance of R&D and marketing, the operation management of manufacturing of pharmaceutical industry is relatively poor. The low asset utilisation rate pointed out this problem. Academic researches have revealed that existing theories of operation management of manufacturing, such as action research, set-up reduction, teamwork, continuous improvement, collaboration, and involvement, are applicable and beneficial to pharmaceutical industry rather than waiting for the technology breakthroughs....
Détails de conformité du produit
Personne responsable dans l'UE